Cosmos Healthcare Advances Brain Health Diagnostics with Neuromap and QPAN Integration

Cosmos Healthcare has integrated two advanced artificial intelligence (AI)-based systems, Neuromap and QPAN, to transform the diagnosis and treatment of neurological and neurodevelopmental conditions. This collaboration aims to enhance diagnostic accuracy, improve therapeutic outcomes, and establish a new benchmark in patient-centered brain health care.

Neuromap, developed by Dr. Alptekin Aydin, utilizes quantitative electroencephalography (qEEG) data to create detailed and individualized brain activity maps. These maps provide clinicians with precise insights into specific areas of brain dysregulation, enabling them to understand and address the unique neurological profiles of patients. The system also integrates neuropsychological principles to guide targeted treatment strategies tailored to individual patient profiles.

QPAN (qEEG Guided Personalized AI-based Neuromodulation) complements Neuromap by leveraging advanced AI algorithms to analyze qEEG data and identify subtle patterns that may indicate neurological abnormalities. Together, these systems enable clinicians to develop highly individualized treatment plans that optimize outcomes for various conditions, including autism spectrum disorder, epilepsy, Alzheimer’s disease, anxiety, depression, and attention deficit hyperactivity disorder (ADHD).

QPAN incorporates state-of-the-art neuromodulation techniques, such as Transcranial Magnetic Stimulation (TMS) and Transcranial Direct Current Stimulation (tDCS), to modulate brainwave activity and restore balance to dysregulated areas. These non-invasive methods target specific brain regions to improve cognitive, emotional, and behavioral outcomes. For example, QPAN enhances attention and focus by adjusting theta and beta activity, improves emotional regulation by stabilizing delta and gamma waves, facilitates communication by targeting temporal regions, and boosts sensory integration by modulating activity in sensory-processing brain regions. The iterative process of QPAN ensures that progress is regularly monitored and treatment plans are adjusted as needed, fostering long-term improvements in brain function.

Neuromap and QPAN have significant implications for the treatment of autism spectrum disorder. By identifying dysregulated brain activity, such as excessive delta waves or low gamma power, these tools enable targeted interventions to address challenges such as inattention, sensory processing issues, and emotional dysregulation.

In epilepsy, the systems identify paroxysmal activity to guide precise therapeutic approaches. For Alzheimer’s disease and age-related cognitive decline, biomarkers like occipital alpha activity are analyzed to support early diagnosis and intervention strategies.

By integrating data-driven diagnostics with multidisciplinary treatment planning, the systems offer comprehensive therapeutic recommendations spanning behavioral therapies, neuromodulation, and lifestyle adjustments. Neuromap provides the foundation for interventions like Applied Behavior Analysis (ABA) and Cognitive Behavioral Therapy (CBT), while QPAN’s AI-driven analysis ensures that interventions are precisely tailored to each patient’s neurological characteristics. This synergy leverages neuroplasticity—the brain’s ability to reorganize and adapt—to maximize therapeutic outcomes and promote lasting improvements.

Their evidence-based approach ensures measurable progress, with follow-up qEEG scans tracking changes in brainwave activity and informing real-time adjustments to treatment strategies. The systems also encourage family involvement by providing actionable insights for creating supportive home environments.

The combined capabilities of Neuromap and QPAN illustrate AI’s potential to transform neurological care. By offering precise diagnostics and individualized therapeutic pathways, these tools represent the future of personalized neuroscience.